BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31727132)

  • 1. Obesity in achondroplasia patients: from evidence to medical monitoring.
    Saint-Laurent C; Garde-Etayo L; Gouze E
    Orphanet J Rare Dis; 2019 Nov; 14(1):253. PubMed ID: 31727132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
    Saint-Laurent C; Garcia S; Sarrazy V; Dumas K; Authier F; Sore S; Tran A; Gual P; Gennero I; Salles JP; Gouze E
    PLoS One; 2018; 13(4):e0195876. PubMed ID: 29652901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achondroplasia: a comprehensive clinical review.
    Pauli RM
    Orphanet J Rare Dis; 2019 Jan; 14(1):1. PubMed ID: 30606190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological Manifestations of Achondroplasia.
    Bodensteiner JB
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):105. PubMed ID: 31782047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
    Webster MK; Donoghue DJ
    EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
    Aviezer D; Golembo M; Yayon A
    Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low bone mineral density in achondroplasia and hypochondroplasia.
    Matsushita M; Kitoh H; Mishima K; Kadono I; Sugiura H; Hasegawa S; Nishida Y; Ishiguro N
    Pediatr Int; 2016 Aug; 58(8):705-8. PubMed ID: 26716907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achondroplasia: from genotype to phenotype.
    Richette P; Bardin T; Stheneur C
    Joint Bone Spine; 2008 Mar; 75(2):125-30. PubMed ID: 17950653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
    Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
    Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
    Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
    Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the achondroplasia mutation on FGFR3 dimerization and FGFR3 structural response to fgf1 and fgf2: A quantitative FRET study in osmotically derived plasma membrane vesicles.
    Sarabipour S; Hristova K
    Biochim Biophys Acta; 2016 Jul; 1858(7 Pt A):1436-42. PubMed ID: 27040652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurologic manifestations of achondroplasia.
    Hecht JT; Bodensteiner JB; Butler IJ
    Handb Clin Neurol; 2014; 119():551-63. PubMed ID: 24365319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Achondroplasia.
    Horton WA; Hall JG; Hecht JT
    Lancet; 2007 Jul; 370(9582):162-172. PubMed ID: 17630040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achondroplasia.
    Baujat G; Legeai-Mallet L; Finidori G; Cormier-Daire V; Le Merrer M
    Best Pract Res Clin Rheumatol; 2008 Mar; 22(1):3-18. PubMed ID: 18328977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Snail1 is a transcriptional effector of FGFR3 signaling during chondrogenesis and achondroplasias.
    de Frutos CA; Vega S; Manzanares M; Flores JM; Huertas H; Martínez-Frías ML; Nieto MA
    Dev Cell; 2007 Dec; 13(6):872-83. PubMed ID: 18061568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anesthesia for bariatric surgery in an achondroplastic dwarf with morbid obesity.
    Abrão MA; da Silveira VG; de Almeida Barcellos CF; Cosenza RC; Carneiro JR
    Rev Bras Anestesiol; 2009; 59(1):79-86. PubMed ID: 19374219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
    Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
    Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
    Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Achondroplasia: pathogenesis and implications for future treatment.
    Laederich MB; Horton WA
    Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.